skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


November may have had the lowest deal volume of the year to date, but five hefty fundraisings pushed the total takings of the first 11 months of 2017 to more than $5.9bn. With one more month to go, will 2017 succeed in surpassing $6bn in total deal value, and claim the title of most bountiful year since 2013?






[Editors' note: For more details about VC deals in 2017 and previous years, go to Medtech Insight's VC deals tracker.]



2017 could set a five-year record for the most venture capital and private-equity dollars raised by emerging medtech companies, even smashing through the $6bn barrier for the first time, after November recorded several hefty fundraisings.



Of the 19 medtech VC financing deals recorded by Medtech Insight's VC deals tracker, the 17 that disclosed financial details raised an impressive $622.1m. The shortfall from the very modest deal volume – 10 less than the month before and three less than in November last year – was mitigated by the significant deal value coming from the month's top five transactions that raised $50m and over. (See Figure 1.)



Figure 1

No. Of Deals, By Amount Raised, Nov. 2017 Vs Oct. 2017 Vs Nov. 2016

Source: Medtech Insight VC deals tracker



November's rich pickings have boosted total deal value this year to date to $5.90bn, just over $100m – a very feasible target to hit for December – to exceed $6bn and break the five-year record. (See Figure 2.). Looking at the deal value, month-by-month over the last five years, 2017 has proven to be a consistently solid performer. Bar February, where its takings were the lowest compared to the same month in the previous years, there were five months – January, March, May, September and November – where 2017 outshone every year back to 2013.



Figure 2

5-Year Trend: Monthly VC Deal Value, January-November, 2013-2017

Source: Medtech Insight VC deals tracker



Consumer Genomics Rising Star

November's top-five companies in financing totals came from the two traditionally attractive product/therapy areas of investment – IVD and cardiology. (See Table 1.)




Table 1

Top-5 VC Deals, November 2017

Source:Medtech Insight VC deals tracker



Geographic base

Product/ Therapy sector

Amount raised

Financing round

Total investment



California, US



Series B




Beijing, China







California, US







Zurich, Switzerland

Cardiology /Regenerative medicine

€45m ($52m)

Series C



EBR Systems

California, US








Although a mere fraction of the $900m series B funds raised by Grail in March, Progenity Inc.'s none-too-paltry $125m series B was the biggest round in November. This, and the other two companies in the top three – Annoroad and Counsyl – all target similar markets by offering gene tests and testing services for women's health, reproductive health and cancer management. California-based Progenity, which is focused more on the clinical community, said it will use the funds to further enhance its existing portfolio in these areas, but it is also looking to expand into gastrointestinal health and the new capital will accelerate development of its GI platform of precision molecular diagnostics tools, precision therapeutics, microbiome analytics, and consumer health nutrition.



Beijing-based Annoroad – the second largest round with $105m – leverages its proprietary next-generation sequencing platform to offer diagnostic services to the clinical community, and directly to consumers. The company has a few well-known names from the Chinese health care investment community within its pool of backers, including Ping An Ventures and GTJA Investment Group. Annoroad said it will use the proceeds to scale up its business and accelerate its R&D pipeline among other things. Counsyl, like, offers its services mainly to consumers and is more focused on prenatal testing, women's health and hereditary disorders.



It may not be surprising to some that the top three deals involved companies that have similar offerings and highlight not only investors' belief in the huge potential of the non-invasive prenatal testing market segment, but also in the consumer genomics marketplace. This point was underscored by Paula Dowdy, Illumina Inc.'s senior VP and general manager of commercial operations for EMEA, in an interview with Medtech Insight earlier this year. While companies like and 23andMe Inc. have met with commercial success in the US, consumer genomics companies like these have yet to really take off in Europe. But the next five years should see things turn around, Dowdy predicted. (Also see "Illumina Enters Second Wave Of Growth As Genomics Demand Swells" - Medtech Insight, 27 Jul, 2017.).



Matching prior months, IVD was the most popular sector in the number of deals in November, but cardiology, usually in the second position, was beaten last month by diabetes management. (See Figure 3.)



Figure 3

No. Of Deals, By Product/Therapy Areas, November 2017

Source:Medtech Insight VC deals tracker



From the editors of Clinica

Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: